When comparing the PDA model, which is induced by a Kras mutant and caerulein, with the skin carcinogenesis model, where a carcinogenic agent induces Ras mutations (initiation phase) followed by clonal expansion by a phorbol ester (promotion phase), caerulein appears to act as a tumor-promoting agent [64]. This evidence concerns the gene KRAS and Patent ductus arteriosus.